To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer, hepatic cancer, etc.).
None
None
(i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Cohort
Prospective
68Ga/18F-PSMA/PSFA
Diagnostic testEach subject receive a single intravenous injection of 68Ga/18F-PSMA/PSFA, and undergo PET/CT imaging within the specificed time.
Standardized uptake value (SUV)
Standardized uptake value (SUV) of PSMA for each target lesion of subject or suspected primary tumor or/and metastasis.
Diagnostic efficacy
The sensitivity, specificity and accuracy of PSMA PET/CT were calculated.
Click on the lead sponsor to view all of their trials.
Tianjin Medical University
Lead sponsor
Tianjin Medical University General Hospital
Collaborator
